Navigation Links
Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
Date:8/24/2011

AMSTERDAM, The Netherlands, August 25, 2011 /PRNewswire/ --

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the first half year of 2011.

Highlights

  • Glybera®:
    • Data showing Glybera produces significant reduction in risk of pancreatitis in LPLD patients presented at European Atherosclerosis Society Meeting
    • CHMP does not consider Glybera approvable at this time
    • Chylomicrons now validated as biomarker for Glybera efficacy; data presented at American Society of Gene and Cell Therapy annual meeting
    • AMT generating further chylomicron data from existing treated patients to support re-examination process
    • Submitted for re-examination, outcome expected before end 2011
  • Collaboration with Institut Pasteur-led Consortium to develop Sanfilippo B gene therapy product for cGMP manufactured material; worth up to € 1.8 million to AMT
  • € 1.1 million funding for Acute Intermittent Porphyria gene therapy product as part of EU Consortium
  • Grant from Dutch Parents Association for Duchenne Muscular Dystrophy gene therapy
  • Appointment of Dr. Carlos R. Camozzi as Chief Medical Officer
  • Key financial figures in line with guidance
  • Cash & cash equivalents of € 9.1 million at June 30, 2011, in line with budget

"We have moved quickly and have already filed an application for re-examination of Glybera, after the initial disappointment with the CHMP opinion in June. We are continuing to collect more data to show that there is a long-term reduction in the incidence of pancreatitis in treated patients.  We will be able to generate the additional data required from the existing treated patients, and the data will come from a trial which we had already pla
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
10. Molecular sleuths track evolution through the ribosome
11. VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/2/2015)... April 02, 2015 One of ... to avoid false negative results. MultiGEN Diagnostics, LLC ... Laboratory Services, LLC (PCLS), has developed a novel ... false negatives, while at the same time maintains ... unique combination is expected to improve the quality ...
(Date:4/1/2015)... , April 1, 2015  Adaptive Biotechnologies ... The Lancet Oncology showing that ... company,s next-generation sequencing-based minimal residual disease (MRD) detection ... MRD test) accurately identifies patients with diffuse large ... relapse after initial treatment, usually several months before ...
(Date:4/1/2015)... Clara, CA (PRWEB) April 01, 2015 ... Force Microscopes (AFM) was selected to receive the ... The New Economy Magazine.    Park NX10 is the premium ... XY and Z scanner linearity, closed-loop detector noise, ... feature, SmartSca n, which allows images ...
(Date:4/1/2015)... 1, 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") ... pleased to announce that Biohaven Pharmaceutical Holding Company ... entered into an agreement with inVentiv Health for ... with their lead compound (BHV-0223). ... of clinical stage neuroscience compounds targeting the glutamatergic ...
Breaking Biology Technology:MultiGEN Diagnostics, LLC Announces the Use of IC-Code™ Technology to Eliminate False Negatives in Molecular Diagnosis. 2Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 2Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 3Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 4Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 5Park Systems Awarded the New Economy Magazine “Best Analytic Instrumentation Company 2014” 2Portage's Biohaven Announces Agreement with inVentiv Health 2Portage's Biohaven Announces Agreement with inVentiv Health 3
... - Attendees at The 18th CPM Resource ... Era , The healthcare industry ... billions allotted for healthcare information technology transformation in,the American ... according to observations shared at the 18th CPM Resource ...
... In spite of continued growth in computational resources ... surrogate to physical reality still faces conceptual and ... of physical reality itself, under conditions of incomplete ... fluctuations. The quantification of this uncertainty has, in ...
... Acquisition LLC (the "Purchaser"), an affiliate of Biotechnology Value Fund ... purchase all of the outstanding shares of Avigen, Inc. (Nasdaq: ... today that it has extended the expiration date for the ... Friday, April 3, 2009. The tender offer was previously set ...
Cached Biology Technology:Experts at Healthcare Conference Support Investments in the Health of Work Culture and Care Processes, Not Just Technology 2Experts at Healthcare Conference Support Investments in the Health of Work Culture and Care Processes, Not Just Technology 3Experts at Healthcare Conference Support Investments in the Health of Work Culture and Care Processes, Not Just Technology 4Opportunities and challenges in uncertainty quantification for complex interacting systems 2BVF Acquisition LLC Extends Avigen Tender Offer to April 3, 2009 2BVF Acquisition LLC Extends Avigen Tender Offer to April 3, 2009 3
(Date:3/12/2015)... -- The mascots of the Atlantic Coast Conference spent ... Forest Baptist Medical Center. They stopped by as part ... Basketball Tournament. Young patients enjoyed bonding with their favorite ... Brenner Children,s Hospital is the pediatric arm ... hospital in northwest North Carolina ...
(Date:3/11/2015)... Mar. 11, 2015 Research and Markets ... "Access Control Market by Product, Application & By ... report to their offering. , This report ... reach $10.4 billion by 2020, with an estimated CAGR ... covers the products types such as contact cards & ...
(Date:3/10/2015)... Colo. , March 10, 2015 ... Flight "Personalized Medicine in Human Space ... and Thomas J. Goodwin , Ph.D. was recently ... of the past two years. Specifically, "Personalized ... most downloaded scientific papers published in 2013 and 2014 ...
Breaking Biology News(10 mins):Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2
... 30,000 still images and video, as well as local ... Encyclopedia of Life via new tools that let the ... science collaboration of unprecedented scale. Experts and citizen ... encyclopedia, which dedicates a Web page to each known ...
... , , , ... biometric technology research and development firm, announced today that GHG ... provide their customers with M2SYS, Bio-SnapON(TM) biometric software solution. , ... biometric recognition capabilities to their web-based employee time tracking software, ...
... FORT WORTH, Texas, Aug. 4 Of the 600,000-800,000 people ... is estimated that by 2010, human trafficking will be the No. 1 ... Ph.D., professor and chairman of the department of forensic and investigative Genetics ... at the University of North Texas (UNT) Health Science ...
Cached Biology News:Cool new tools let public contribute to massive interactive online biodiversity encyclopedia 2Cool new tools let public contribute to massive interactive online biodiversity encyclopedia 3Cool new tools let public contribute to massive interactive online biodiversity encyclopedia 4Cool new tools let public contribute to massive interactive online biodiversity encyclopedia 5Cool new tools let public contribute to massive interactive online biodiversity encyclopedia 6Cool new tools let public contribute to massive interactive online biodiversity encyclopedia 7M2SYS Biometric Software Solution Selected By GHG Corporation 2DNA Helps Reunite Children With Their Families 2DNA Helps Reunite Children With Their Families 3
Goat polyclonal to Lipocalin 2...
Human GCP-2 is a member of the CXC family of chemokines. It also promotes neutrophil chemotaxis and deganulation. GF063 is an 8.0 kDa protein containing 73 amino acid residues....
... Hinge Region By immunoblotting the antibody reacts ... reacts with free MMP-2 or MMP-2 bound ... aqueous glycerol solution Solution in 0.01 ... 50% glycerol and 15 mM sodium azide. ...
human Exodus-2 Research Focus: cytokine/growth factor Storage Temperature: -20C Shipping Temperature: 4C...
Biology Products: